Multidrug resistance proteins and topoisomerase IIα expression in colon cancer: Association with metastatic potential

Pathology

Volumn 35, Issue 4, 2003, Pages 315-318

  Zorzos, Haralampos S ^a,b   Lazaris, Andreas C ^a   Korkolopoulou, Penelope A ^a   Kavantzas, Nikolaos G ^a   Tseleni Balafouta, Sofia ^a   Patsouris, Efstratios S ^a   Tsavaris, Nikolaos V ^a   Davaris, Panagiotis S ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NONE   (Greece)

Author keywords

Chemotherapy; Colon cancer; P glycoprotein; Topoisomerase II

Indexed keywords

ABC TRANSPORTER; DNA TOPOISOMERASE (ATP HYDROLYSING); GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PATIENT; CELL COMPARTMENTALIZATION; CELL PROLIFERATION; COLON CANCER; DRUG TARGETING; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; NUCLEOCYTOPLASMIC TRANSPORT; PROTEIN EXPRESSION; PROTEIN FAMILY;

EID: 0041832359     PISSN: 00313025     EISSN: None     Source Type: Journal    
DOI: 10.1080/0031302031000150524     Document Type: Article

References (21)

1. Cohen AM, Minsky BD, Schilsky RL. Colon cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer Principles & Practice of Oncology. Philadelphia: J.B. Lippincott Company, 1993; 929-77.
2. Meschini S, Calcabrini A, Monti E, et al. Intracellular P-glycoprotein expression is associated with the intrinsic multidrug resistance phenotype in human colon adenocarcinoma cells. Int J Cancer 2000; 87: 615-28.
3. Sinicrope FA, Hart J, Brasitus TA, Michelassi F, Lee JJ, Safa AR. Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy, and disease relapse. Cancer 1994; 74(11): 2908-17.
4. Tokunaga Y, Hosogi H, Hoppou T, Nakagami M, Tokuka A, Ohsumi K. Effects of MDR1/P-glycoprotein expression on prognosis in advanced colorectal cancer after surgery. Oncol Rep 2001; 8(4): 815-9.
5. Meijer GA, Schroeijers AB, Flens MJ, et al. Increased expression of multidrug resistance related proteins Pgp, MRP1, and LRP/MVP occurs early in colorectal carcinogenesis. J Clin Pathol 1999; 52: 450-4.
6. Scheffer GL, Schroeijers AB, Izquierdo MA, Wiemer EAC, Scheper RJ. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 2000; 12: 550-6.
7. Burden DA, Osheroff N. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim Biophys Acta 1998; 1400: 139-54.
8. Hande KR. Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim Biophys Acta 1998; 1400: 173-84.
9. Stewart AJ, Mistry P, Dangerfield W, et al. Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anticancer Drugs 2001; 12(4): 359-67.
10. Korkolopoulou P, Angelopoulou M, Siakantari M, et al. Evaluation of DNA topoisomerase IIα expression provides independent prognostic information in non-Hodgkin's lymphomas. Histopathology 2001; 38: 45-53.
11. Turley H, Comley M, Houlbrook S, et al. The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. Br J Cancer 1997; 75(9): 1340-6.
12. Weinstein RS, Jakate SM, Dominguez JM, et al. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 1991; 51: 2720-6.
13. 2 integrin expression in breast carcinomas evaluated by automated and quantitative immunohistochemistry. Br J Cancer 1998; 77(12): 2274-80.
14. Grogan T, Guptill V, Scheper R, Spier C, Dalton W, Weinstein R. Altered cell adhesion molecule (CAM) expression in P-glycoprotein rich myleoma plasma cells. J Cell Biol 1990; 111: 156a.
15. Mirsky R, Jessen KR, Schachner M, Goridis C. Distribution of the adhesion molecules N-CAM and L1 on peripheral neurons and glia in adults rats. J Neurocytol 1986; 15(6): 799-815.
16. Kobayashi R, Hirakawa H, Puri P. Is intestinal neuronal dysplasia a disorder of the neuromuscular junction? J Pediatr Surg 1996; 31(4): 575-9.
17. Iwahashi T, Okochi E, Ariyoshi K, et al. Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model. Cancer Res 1993; 53: 5475-82.
18. Nokihara H, Nishioka Y, Yano S, et al. Monocyte chemoattractant protein-1 gene modification of multidrug-resistant human lung cancer enhances antimetastatic effect of therapy with anti-P-glycoprotein antibody in SCID mice. Int J Cancer 1999; 80: 773-80.
19. Chin K-V, Ueda K, Pastan I, Gottesman MM. Modulation of the activity of the promoter of the human MDRI gene by Ras and p53. Science 1992; 255: 459-62.
20. Thottassery IV, Zambetti GP, Arimori K, Schuetz EG, Schuetz JD. p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 1997; 94: 11 037-42.
21. Fogt F, Nikulasson ST, Holden JA, Alder SA, Hallgrimsson I, Jessup MI, et al. Topoisomerase II-α expression in normal, inflammatory and neoplastic conditions of the gastric and colonic mucosa. Mod Pathol 1997; 10: 296-302.